Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Breast 2Thoracic 1

Conditions

Melanoma 7Ovarian Neoplasms 6Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Urogenital Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Rectal Neoplasms 2Multiple Myeloma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

Bevacizumab 56Cetuximab 50Fluorouracil 45Leucovorin 39Oxaliplatin 38pembrolizumab 31Specimen Handling 27Irinotecan 25Magnetic Resonance Spectroscopy 17Biopsy 17Nivolumab 15HMPL-013 13Folfox protocol 13Capecitabine 13Gemcitabine 12Cisplatin 12trifluridine tipiracil drug combination 11Panitumumab 11Carboplatin 11Pemetrexed 9IFL protocol 9encorafenib 8balstilimab 8Standard of Care 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7Educational Status 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × aldesleukin × 90 days × Clear all
NCT01174121 2026-06-05

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
332 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
210 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡